🇺🇸 FDA
Patent

US 7662999

Recognition of oligosaccharide molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases

granted A61PA61P31/04A61P37/02

Quick answer

US patent 7662999 (Recognition of oligosaccharide molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases) held by The United States of America as represented by the Department of Health and Human Services (DHHS) expires Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Department of Health and Human Services (DHHS)
Grant date
Tue Feb 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P31/04, A61P37/02, A61P43/00